Ipenoxazone (MLV-6976)

目录号: GC31181纯度: >98%同义词: 伊培沙宗; MLV-6976; NC-1200
Ipenoxazone (MLV-6769) 是一种强效和中枢作用的肌肉松弛剂。

Ipenoxazone (MLV-6976)
Cas No.: 104454-71-9
规格价格库存数量操作
1mg¥13,405.00现货
1
5mg¥21,456.00现货
1
10mg¥34,335.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Ipenoxazone is a potent and centrally acting muscle relaxant.

Ipenoxazone is a potent and centrally acting muscle relaxant[1]. An intravenous injection of 2 mg/kg Ipenoxazone causes a reduction of electromyographic activity which reaches a maximum within 3 min after the injection. Within 1 min after the injection of Ipenoxazone at a dose of 4 mg/kg, the blood pressure changes from a control level of 138±9 mmHg to a minimum level of 98±9 mmHg (n=6) but it rapidly returns to the control level within 1 to 2 min, while the rigidity is still reduced significantly at that time. High doses (greater than 30 mg/kg i.p.) of Ipenoxazone produces a transient and dose-dependent sedation in almost all mice about 5 min after its administration[2].

[1]. Kimura A, et al. Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5- phenyl-1,3-oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats. Eur J Pharmacol. 1988 Jul 26;152(1-2):55-62. [2]. Masaki M, et al. A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity. Br J Pharmacol. 1986 Sep;89(1):219-28.

实验参考方法 Experimental Reference Method

Animal experiment:

Experiments are performed on 31 adult male rats (Wistar 310 to 430 g, 3 to 7 months of age) anesthetized with chloralose-urethane (50 and 500 mg/kg i.p., respectively). Ipenoxazone is administrated i.v. at 0.05 to 0.1 mL/100 g body weight (20 to 40 s per injection). These four different doses of Ipenoxazone (0.3, 1, 3 and 10 mg/kg) are administrated cumulatively, from small doses to larger doses. It is usually waited about 10 to 30 min between each trial or until all effects of the drug on the bladder have disappeared[1].

References:

[1]. Kimura A, et al. Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5- phenyl-1,3-oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats. Eur J Pharmacol. 1988 Jul 26;152(1-2):55-62.
[2]. Masaki M, et al. A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity. Br J Pharmacol. 1986 Sep;89(1):219-28.

产品文档 Product Documents

化学性质Chemical Properties

CAS 号
104454-71-9
同义词
伊培沙宗; MLV-6976; NC-1200
SMILES
O=C1O[C@H](C2=CC=CC=C2)[C@H](CC(C)C)N1CCCN3CCCCCC3
分子式
C22H34N2O2
分子量
358.52 g/mol
溶解性
Soluble in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol